Navigation Links
GranuFlo Lawsuit Consolidation Supported by Fresenius Medical Care, Bernstein Liebhard LLP Reports
Date:1/12/2013

New York, New York (PRWEB) January 12, 2013

Fresenius Medical Care, the maker of GranuFlo and NaturaLyte dialysis products, supports the consolidation of all federally-filed GranuFlo lawsuits in a multidistrict litigation in U.S. District Court, District of Massachusetts, Bernstein Liebhard LLP reports. In a brief filed with the U.S. Judicial Panel on Multidistrict Litigation (JPML) on January 3rd, the company said it is facing 37 federal claims filed in various jurisdictions involving allegations that GranuFlo and NaturaLyte caused plaintiffs to suffer serious cardiopulmonary injuries. (In re Fresenius GranuFlo/Naturalyte Dialysate Litigation, MDL No. 2428 (JPML))

“GranuFlo and NaturaLyte were administered to thousands of dialysis patients. Because this has the potential to become a large litigation, we agree that consolidation of the claims in a single court is appropriate,” says Bernstein Liebhard LLP, a nationwide law firm representing the victims of defective drugs and medical devices. The Firm is currently offering free legal evaluations to victims of cardiac arrest, heart attacks, stroke, sudden cardiac death, or other serious heart problems allegedly caused by GranuFlo and NaturaLyte.

GranuFlo Recall
GranuFlo and NaturaLyte are used during dialysis to reduce the amount of acid in the blood. In March 2012, Fresenius issued an “Urgent Product Notification” to its customer clinics warning of possible heart risks associated with the products. According to the notice, both have the potential to cause a rapid and unsafe elevation of bicarbonate, which creates a substantially increased risk of cardiopulmonary arrest and death. The U.S. Food & Drug Administration (FDA) would later deem Fresenius’ notification a Class I recall, its most urgent type of recall.*

Months before the GranuFlo recall, Fresenius issued a memo to dialysis clinics within its own network that warned of the risks associated with GranuFlo and NaturaLyte, and advised doctors practicing at those facilities to adjust dosage accordingly. According to a report from The New York Times, the November 2011 document reported that 941 patients had suffered cardiac arrest inside Fresenius clinics in 2010. Fresenius’ own medical staff had determined that patients with high levels of bicarbonate in their blood had about six times the risk of cardiac arrest as those with lower levels, according to the document. In the wake of the GranuFlo recall, the FDA launched investigation to determine if Fresenius Medical Care’s failure to issue an earlier warning to its customer clinics may have violated federal law, according to the Times**

Dialysis patients who suffered heart attacks, sudden cardiac death, and other catastrophic heart side effects within 48 hours of a dialysis treatment with GranuFlo or NaturaLyte may be entitled to compensation for medical expenses, lost wages, pain and suffering, and more. Learn more about filing a GranuFlo lawsuit by visiting Bernstein Liebhard LLP’s website, http://www.consumerinjurylawyers.com. For additional information, contact a lawyer at Bernstein Liebhard LLP today by calling (877) 779-1414.

*fda.gov/MedicalDevices/Safety/ListofRecalls/ucm309990.htm
**nytimes.com/2012/06/15/health/fda-investigates-fresenius-for-failure-to-warn-of-risk.html

About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993, including those who have been harmed by dangerous drugs, defective medical devices and consumer products. The firm has been named by The National Law Journal to the “Plaintiffs’ Hot List,” recognizing the top plaintiffs’ firms in the country, for the past 10 consecutive years.

Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
(877) 779-1414

ATTORNEY ADVERTISING. © 2013 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414. The lawyer responsible for this advertisement in the State of Connecticut is Amy L. Abate. Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Contact Information:
Felecia L. Stern, Esq.
Bernstein Liebhard LLP
info(at)consumerinjurylawyers(dot)com
http://www.consumerinjurylawyers.com

Read the full story at http://www.prweb.com/releases/granuflo-lawsuit/granuflo-recall/prweb10316467.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. New Lawsuit on Injuries from Zimmer Durom Cup: Now, AttorneyOne Can Provide Advice
2. New Lawsuit Alleges Fosamax Increases Risk of Injury: Now, AttorneyOne Can Provide Advice
3. Stryker Hip Recall Lawsuits Being Evaluated by Bernstein Liebhard LLP, Following Recall of Stryker Rejuvenate and ABG II Modular Neck Stems
4. “Nap Nanny” Deaths Grounds for Lawsuit
5. DrugRisk Adds Latest Health Warnings and Lawsuit Updates for Yaz
6. DePuy ASR Hip Recall, Transvaginal Mesh Lawsuit Updates: Bernstein Liebhard LLP Looks Forward to Start of First Bellwether Trials in New Year
7. New Lawsuit on DePuy Hip Implants Metal Poisoning: Now, AttorneyOne Can Provide Advice
8. New Lawsuit on Avodart Prostate Cancer: Now, AttorneyOne Can Provide Advice
9. Propecia Lawsuits Being Investigated by Bernstein Liebhard LLP, as Propecia Litigation Pending in New Jersey Superior Court Continues to Move Forward
10. Pradaxa Lawsuits Being Investigated by Bernstein Liebhard LLP, as Next Conference in Federal Pradaxa Litigation Set for January 10th
11. Warning Claim on Alleged Defective Wright Hip Implant Lawsuit Dismissed: AttorneyOne Informs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... ... February 23, 2017 , ... ... , media relations, content marketing, social media management, corporate communications, SEO and cause ... the state and in nearby New Hampshire, Massachusetts and Canada, Rosica will focus ...
(Date:2/23/2017)... Colorado (PRWEB) , ... February 23, 2017 , ... ... Magazine, an exciting, new, interactive publication where generations converge and explore the world ... expand their worldview, Dialog Magazine enables readers to gain understanding, increase empathy, and ...
(Date:2/23/2017)... , ... February 23, 2017 , ... ... new partnership with the Rhode Island Consortium for Autism Research and Treatment (RI-CART) ... for children with autism spectrum disorder (ASD) to see films in an environment ...
(Date:2/23/2017)... ... 2017 , ... Curemark, LLC announced today that the Blüm Study, a Phase ... 3-8 with Autism, is now enrolling at three new sites. These new sites are ... , “There are currently no approved drugs that address the core symptoms of ...
(Date:2/22/2017)... York (PRWEB) , ... February 22, 2017 , ... ... entrance and lobby of a new healthcare contact center in Georgia, PENETRON Specialty ... One of the nation’s largest healthcare systems recently invested $51 million to purchase ...
Breaking Medicine News(10 mins):
(Date:2/23/2017)... , Feb. 23, 2017  Cogentix Medical, Inc. ... and markets innovative proprietary products for the urology market, ... fiscal year ended December 31, 2016 before the market ... The Company will host a conference call and webcast ... Thursday, March 9, 2017 at 11:00 a.m. Eastern Time ...
(Date:2/23/2017)... Feb 23, 2017 Research and Markets has announced ... 2016" report to their offering. ... The latest research Menopause Drugs Price Analysis and Strategies - ... The research answers the following questions: ... How are they positioned in the Global Menopause market? ...
(Date:2/23/2017)... 23, 2017 Research and Markets has announced ... - 2016" report to their offering. ... The latest research Fibromyalgia Drugs Price ... in the global Fibromyalgia market. The research answers the ... marketed for Fibromyalgia and their clinical attributes? How are they positioned ...
Breaking Medicine Technology: